Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis

BackgroundThe COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systemati...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2022-02, Vol.12 (2), p.e044661-e044661
Main Authors: Han, Shuting, Zhuang, Qingyuan, Chiang, Jianbang, Tan, Sze Huey, Chua, Gail Wan Ying, Xie, Conghua, Chua, Melvin L K, Soon, Yu Yang, Yang, Valerie Shiwen
Format: Article
Language:English
Subjects:
Cancer
Coronaviruses
COVID-19
Databases, Factual
epidemiology
Fatalities
Humans
Medical diagnosis
Meta-analysis
Mortality
Neoplasms
Oncology
SARS-CoV-2
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systematic review and meta-analysis (MA).MethodsSystematic review was performed through online databases, PubMed, Medline and Google Scholar, with keywords listed in the Methods section (1 November 2019–31 December 2020). Studies with clinical outcomes of at least 10 COVID-19 patients and at least one with a diagnosis of cancer were included. The studies for MA were assessed with PRISMA guidelines and appraised with Newcastle-Ottawa Scale. The data were pooled using a random-effects model using STATA software. The main outcomes were planned before data collection, including proportion of patients with cancer among COVID-19 populations, relative risk (RR) of severe outcomes and death of patients with cancer compared with general COVID-19 patients.ResultsWe identified 57 case series (63 413 patients), with 230 patients with cancer with individual patient data (IPD). We found that the pooled proportion of cancer among COVID-19 patients was 0.04 (95% CI 0.03 to 0.05, I2=97.69%, p
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2020-044661